<DOC>
	<DOC>NCT00337701</DOC>
	<brief_summary>This study will evaluate the signs and symptoms associated with Fuzeon injection (90mg sc) using the B2000 needle-free injection device, in HIV-1 positive patients experienced to Fuzeon treatment, but having difficulty tolerating long-term (&gt;4 weeks) administration of Fuzeon with the standard needle and syringe. Patients will be randomized to the B2000 device or the standard needle and syringe for 4 weeks; all patients will use the B2000 device for the next 4 weeks. The anticipated time on study treatment is &lt;3 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>adult patients &gt;=16 years of age; current or former Fuzeon user who may benefit from needlefree administration of Fuzeon; naive to use of the B2000 device; positive test results for human immunodeficiency virus infection. patients naive to Fuzeon; inability to selfinject Fuzeon, or no reliable caregiver to administer injections; evidence of active, untreated, opportunistic infections.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>